Regulator okays Insulet’s insulin pump in US to treat type 2 diabetes
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Insulet Corporation, a tubeless insulin pump maker, got clearance from the US Food and Drug Administration to add diabetes type 2 adult patients.
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24%.
Bharti Jayshankar February 29, 2024: From packaged snacks to sugary drinks, the allure of ultra-processed foods (UPF) has become a staple in many.
Bharti Jayshankar January 26, 2024: A recent study has uncovered an unexpected benefit of medications commonly prescribed for obesity and type 2 diabetes:.
HQ Team October 27, 2023: Millions of individuals managing diabetes rely on metformin to regulate their blood sugar levels. Recent research highlights the.
HQ Team June 23, 2023: The global population of people living with diabetes may more than double to 1.3 billion from the current.
HQ Team June 21, 2023: Patients with cancer are markedly insulin-resistant, similar to people with type 2 diabetes, and it can lead to.
HQ Team June 8, 2023: A new study analyzing the PIONEER (Peptide Innovation for Early Diabetes Treatment) clinical trials data has revealed the.
INPEFA is an inhibitor of both sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). This class of SGLT inhibitors was recommended as.